154 related articles for article (PubMed ID: 36905915)
1. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors.
Wu K; He R; Li Z; Qiu K; Xiao G; Peng L; Meng X; Zheng C; Zhang Z; Cai Q
Eur J Med Chem; 2023 May; 251():115237. PubMed ID: 36905915
[TBL] [Abstract][Full Text] [Related]
2. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.
Zhang Y; Chan S; He R; Liu Y; Song X; Tu ZC; Ren X; Zhou Y; Zhang Z; Wang Z; Zhou F; Ding K
Eur J Med Chem; 2022 Dec; 244():114862. PubMed ID: 36308779
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
[TBL] [Abstract][Full Text] [Related]
4. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
Zhang L; Moccia M; Briggs DC; Bharate JB; Lakkaniga NR; Knowles P; Yan W; Tran P; Kharbanda A; Wang X; Leung YK; Frett B; Santoro M; McDonald NQ; Carlomagno F; Li HY
J Med Chem; 2022 Jan; 65(2):1536-1551. PubMed ID: 35081714
[TBL] [Abstract][Full Text] [Related]
6. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
7. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
8. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
Wang M; Naganna N; Sintim HO
Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
[TBL] [Abstract][Full Text] [Related]
9. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
10. Discovery and optimization of selective RET inhibitors via scaffold hopping.
Luo Z; Wang L; Fu Z; Shuai B; Luo M; Hu G; Chen J; Sun J; Wang J; Li J; Chen S; Zhang Y
Bioorg Med Chem Lett; 2021 Sep; 47():128149. PubMed ID: 34058344
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
[TBL] [Abstract][Full Text] [Related]
12. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
13. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
[No Abstract] [Full Text] [Related]
14. Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
[TBL] [Abstract][Full Text] [Related]
15. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
16. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX; Li QQ; Cai J; Wu JZ; Wang JJ; Zhang MY; Wang QX; Tong ZJ; Yang J; Wei TH; Zhou Y; Dai WC; Ding N; Leng XJ; Sun SL; Xue X; Yu YC; Yang Y; Li NG; Shi ZH
J Med Chem; 2024 Mar; 67(6):4346-4375. PubMed ID: 38484122
[TBL] [Abstract][Full Text] [Related]
18. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
19. Discovery of
Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
[TBL] [Abstract][Full Text] [Related]
20. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]